An association study of the cholesteryl ester transfer protein TaqI B polymorphism with late onset Alzheimer's disease

Liana Fidani, Antonis Goulas, Richard Crook, Ronald Carl Petersen, Eric George Tangalos, Alexandros Kotsis, John Hardy

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Cholesteryl ester transfer protein (CETP) is reportedly able to affect the amount of cholesterol available for deposition and/or removal from peripheral tissues, in its capacity to mediate the transfer of cholesterol from high density lipoprotein (HDL) to very low density lipoprotein, in exchange for triacylglycerols from the latter. The TaqI B polymorphism of the human CETP gene has been associated with decreased CETP mass and an increase in HDL-cholesterol. While many studies have addressed the atherogenic or anti-atherogenic potential of this polymorphism, little is known about its effect on neurodegeneration, despite the fact that CETP is expressed in the brain and the disturbance of cholesterol homeostasis appears to be an important factor in the pathogenesis of Alzheimer's disease (AD). In this report, we have compared the distribution of the TaqI B polymorphism in an independent population of 102 clinically diagnosed late onset AD patients and a spousal control group of 97 individuals. We have also examined the possible interaction between this polymorphism and two other polymorphisms suspected of affecting cholesterol flux, namely apolipoprotein E APOE ε4, and lipoprotein lipase LPLS447X. No statistically significant differences have emerged with respect to either genotype or allele frequencies between the AD and control populations. CETP TaqI B did not interact significantly with either APOE ε4 or LPLS447X, in this study.

Original languageEnglish (US)
Pages (from-to)152-154
Number of pages3
JournalNeuroscience Letters
Volume357
Issue number2
DOIs
StatePublished - Mar 4 2004

Fingerprint

Cholesterol Ester Transfer Proteins
Alzheimer Disease
Cholesterol
HDL Cholesterol
Apolipoprotein E4
VLDL Lipoproteins
Lipoprotein Lipase
Gene Frequency
Population
Triglycerides
Homeostasis
Genotype
IgA receptor
Control Groups
Brain
Genes

Keywords

  • Alzheimer's disease
  • Apolipoprotein E
  • Cholesteryl ester transfer protein
  • Genetics
  • Lipoprotein lipase
  • Polymorphism

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

An association study of the cholesteryl ester transfer protein TaqI B polymorphism with late onset Alzheimer's disease. / Fidani, Liana; Goulas, Antonis; Crook, Richard; Petersen, Ronald Carl; Tangalos, Eric George; Kotsis, Alexandros; Hardy, John.

In: Neuroscience Letters, Vol. 357, No. 2, 04.03.2004, p. 152-154.

Research output: Contribution to journalArticle

Fidani, Liana ; Goulas, Antonis ; Crook, Richard ; Petersen, Ronald Carl ; Tangalos, Eric George ; Kotsis, Alexandros ; Hardy, John. / An association study of the cholesteryl ester transfer protein TaqI B polymorphism with late onset Alzheimer's disease. In: Neuroscience Letters. 2004 ; Vol. 357, No. 2. pp. 152-154.
@article{77c4e9ea86fd4983adf1814d203afcfa,
title = "An association study of the cholesteryl ester transfer protein TaqI B polymorphism with late onset Alzheimer's disease",
abstract = "Cholesteryl ester transfer protein (CETP) is reportedly able to affect the amount of cholesterol available for deposition and/or removal from peripheral tissues, in its capacity to mediate the transfer of cholesterol from high density lipoprotein (HDL) to very low density lipoprotein, in exchange for triacylglycerols from the latter. The TaqI B polymorphism of the human CETP gene has been associated with decreased CETP mass and an increase in HDL-cholesterol. While many studies have addressed the atherogenic or anti-atherogenic potential of this polymorphism, little is known about its effect on neurodegeneration, despite the fact that CETP is expressed in the brain and the disturbance of cholesterol homeostasis appears to be an important factor in the pathogenesis of Alzheimer's disease (AD). In this report, we have compared the distribution of the TaqI B polymorphism in an independent population of 102 clinically diagnosed late onset AD patients and a spousal control group of 97 individuals. We have also examined the possible interaction between this polymorphism and two other polymorphisms suspected of affecting cholesterol flux, namely apolipoprotein E APOE ε4, and lipoprotein lipase LPLS447X. No statistically significant differences have emerged with respect to either genotype or allele frequencies between the AD and control populations. CETP TaqI B did not interact significantly with either APOE ε4 or LPLS447X, in this study.",
keywords = "Alzheimer's disease, Apolipoprotein E, Cholesteryl ester transfer protein, Genetics, Lipoprotein lipase, Polymorphism",
author = "Liana Fidani and Antonis Goulas and Richard Crook and Petersen, {Ronald Carl} and Tangalos, {Eric George} and Alexandros Kotsis and John Hardy",
year = "2004",
month = "3",
day = "4",
doi = "10.1016/j.neulet.2003.11.071",
language = "English (US)",
volume = "357",
pages = "152--154",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - An association study of the cholesteryl ester transfer protein TaqI B polymorphism with late onset Alzheimer's disease

AU - Fidani, Liana

AU - Goulas, Antonis

AU - Crook, Richard

AU - Petersen, Ronald Carl

AU - Tangalos, Eric George

AU - Kotsis, Alexandros

AU - Hardy, John

PY - 2004/3/4

Y1 - 2004/3/4

N2 - Cholesteryl ester transfer protein (CETP) is reportedly able to affect the amount of cholesterol available for deposition and/or removal from peripheral tissues, in its capacity to mediate the transfer of cholesterol from high density lipoprotein (HDL) to very low density lipoprotein, in exchange for triacylglycerols from the latter. The TaqI B polymorphism of the human CETP gene has been associated with decreased CETP mass and an increase in HDL-cholesterol. While many studies have addressed the atherogenic or anti-atherogenic potential of this polymorphism, little is known about its effect on neurodegeneration, despite the fact that CETP is expressed in the brain and the disturbance of cholesterol homeostasis appears to be an important factor in the pathogenesis of Alzheimer's disease (AD). In this report, we have compared the distribution of the TaqI B polymorphism in an independent population of 102 clinically diagnosed late onset AD patients and a spousal control group of 97 individuals. We have also examined the possible interaction between this polymorphism and two other polymorphisms suspected of affecting cholesterol flux, namely apolipoprotein E APOE ε4, and lipoprotein lipase LPLS447X. No statistically significant differences have emerged with respect to either genotype or allele frequencies between the AD and control populations. CETP TaqI B did not interact significantly with either APOE ε4 or LPLS447X, in this study.

AB - Cholesteryl ester transfer protein (CETP) is reportedly able to affect the amount of cholesterol available for deposition and/or removal from peripheral tissues, in its capacity to mediate the transfer of cholesterol from high density lipoprotein (HDL) to very low density lipoprotein, in exchange for triacylglycerols from the latter. The TaqI B polymorphism of the human CETP gene has been associated with decreased CETP mass and an increase in HDL-cholesterol. While many studies have addressed the atherogenic or anti-atherogenic potential of this polymorphism, little is known about its effect on neurodegeneration, despite the fact that CETP is expressed in the brain and the disturbance of cholesterol homeostasis appears to be an important factor in the pathogenesis of Alzheimer's disease (AD). In this report, we have compared the distribution of the TaqI B polymorphism in an independent population of 102 clinically diagnosed late onset AD patients and a spousal control group of 97 individuals. We have also examined the possible interaction between this polymorphism and two other polymorphisms suspected of affecting cholesterol flux, namely apolipoprotein E APOE ε4, and lipoprotein lipase LPLS447X. No statistically significant differences have emerged with respect to either genotype or allele frequencies between the AD and control populations. CETP TaqI B did not interact significantly with either APOE ε4 or LPLS447X, in this study.

KW - Alzheimer's disease

KW - Apolipoprotein E

KW - Cholesteryl ester transfer protein

KW - Genetics

KW - Lipoprotein lipase

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=1242314752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242314752&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2003.11.071

DO - 10.1016/j.neulet.2003.11.071

M3 - Article

VL - 357

SP - 152

EP - 154

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2

ER -